Molecular profiling of non-small-cell lung cancer patients with or without brain metastases included in the randomized SAFIR02-LUNG trial and association with intracranial outcome - Institut Paoli-Calmettes
Article Dans Une Revue Lung Cancer Année : 2022

Molecular profiling of non-small-cell lung cancer patients with or without brain metastases included in the randomized SAFIR02-LUNG trial and association with intracranial outcome

Maryam Karimi
Nicolas Girard
  • Fonction : Auteur
Julien Mazieres
Marta Jimenez
  • Fonction : Auteur
Sabrina Yara
  • Fonction : Auteur
Ivan Bieche

Résumé

Lung cancer remains the most frequent cause of brain metastases (BMs) and is responsible for high morbidity and mortality. Intracranial response to systemic treatments is inconsistent due to several mechanisms: genomic heterogeneity, blood-tumor barrier, and the brain-specific microenvironment. We conducted a study using data from the SAFIR02-LUNG trial. The primary objective was to compare the molecular profiles of non-small-cell lung cancer (NSCLC) with or without BMs. The secondary objective was to explore central nervous system (CNS) outcomes with various maintenance treatment regimens.
Fichier principal
Vignette du fichier
S0169500222004330.pdf (883.52 Ko) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03925563 , version 1 (22-07-2024)

Licence

Identifiants

Citer

Alice Mogenet, Fabrice Barlesi, Benjamin Besse, Stefan Michiels, Maryam Karimi, et al.. Molecular profiling of non-small-cell lung cancer patients with or without brain metastases included in the randomized SAFIR02-LUNG trial and association with intracranial outcome. Lung Cancer, 2022, 169, pp.31-39. ⟨10.1016/j.lungcan.2022.05.004⟩. ⟨hal-03925563⟩
290 Consultations
35 Téléchargements

Altmetric

Partager

More